The pattern recognition module provides an execution environment for Two Crows recognition and related indicators on Insulet. This view tracks pattern recognition signals tied to momentum and continuation to support structured performance interpretation without implying advice.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. Two Crows is a 3-day pattern that warns about a possible future trend reversal for Insulet.
Insulet Technical Analysis Modules
Most technical analysis of Insulet help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Insulet from various momentum indicators to cycle indicators. When you analyze Insulet charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people. A high-level view of Insulet emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 11.17, profit margin of 9.12%. Insulet has a market cap of 16.77 B, ROE of 18.12%.
Methodology
Unless otherwise specified, financial data for Insulet is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Insulet (USA Stocks:PODD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: This report is built using public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR. Normalization for analytical consistency may introduce small timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Insulet may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Insulet inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Insulet often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Insulet Stock in context:
Insulet has a market cap of 16.77 B, operating margin of 18.67%, ROE of 18.12%. Use Your Equity Center to explore allocation context. This includes a position in Insulet across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.
For more information on how to buy Insulet Stock please use our How to Buy Insulet Stock guide.Analysis related to Insulet should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
The market value of Insulet is measured differently than book value, which reflects Insulet accounting equity. Insulet's market capitalization is 16.77 B. With a P/B ratio of 11.17, the market values Insulet well above its book equity. Enterprise value stands at 17.16 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Insulet's intrinsic value and market price are different measures derived from different inputs. For Insulet, key inputs include a P/B ratio of 11.17, a profit margin of 9.12%, ROE of 18.12%, and revenue of 2.71 B. Trading price represents the transaction level agreed by market participants.
Gabriel Shpitalnik ยท Member of Macroaxis Editorial Board